Human Medications, Human Drugs, Animal Medications, Animal Drugs, Pharmacy law, Pharmaceutical law, Compounding law, Sterile and Non Sterile Compounding 797 Compliance, Veterinary law, Veterinary
Compounding Law; Health Care; Awareness of all Types of Compounding Issues;
Pharmacy Benefit Managers (PBMs), Outsourcing Facilities
Food and Drug Administration and Compliance Issues
Friday, February 14, 2020
FDA In Brief: FDA Seeks Input from the Public to Help Prevent Future Lung Injuries Associated with Vaping
The following quote is attributed to FDA Commissioner Stephen M. Hahn, M.D.:
“Since last year, the Food and Drug Administration, the Centers for Disease Control and Prevention and state health authorities have diligently worked to identify substances of concern and characterize the outbreak of lung injuries associated with vaping products.
“We remain deeply concerned about these injuries and deaths and continue to work with other agencies, as well as state and local public health officials, on this complex investigation. National and state data from patient reports and product sample testing suggest vaping products containing tetrahydrocannabinol, particularly from informal sources like friends, or family, or in-person or online dealers, are linked to most cases and play a major role, and that the presence of the compound vitamin E acetate in vaping products is strongly linked to the outbreak.
“Our investigation has brought to the forefront the serious risks of using illicit, black market products. As part of our efforts to mitigate and prevent a potential future outbreak of vaping injuries, we are asking the public for input on additional steps the FDA can take to inform our regulatory work and address the illegal modification of these products.”